The risks, rewards and future potential of biotechnology

Updated: Apr 27

Season 02: episode 06

In this episode, GOLD talks to Claire Skentelbery, Director General, EuropaBio, about the biotech revolution, including how biotech could contribute to the European economy in the future and the readiness of Europe to deliver these innovative therapies at scale.

GOLD also hears from Editor Helena Beer and Assistant Editor Isabel O’Brien as they discuss a recent article ‘A big boom in biotech’, unravelling why the biotech sector is becoming an increasingly attractive option for investors.


A little more on GOLD’s guest…


Claire Skentelbery was appointed Director General (DG) of EuropaBio in 2020. She holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network, working across sectors, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently.

Additional resources


If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Click here to subscribe to the weekly newsletter for more insights from GOLD.